Clinical Trial

Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old

Enrolling by Invitation Phase 3
View on ClinicalTrials.gov →
Summary
This a randomized, blind, controlled clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunogenicity of a two doses vaccination of investigational vaccine with 0,28 day, 0,42 day and 0,56 day immunization schedule in population aged ≥13 years old.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-08-16; most recent amendment 2024-03-06.
Status change: Active, Not Recruiting → Enrolling by Invitation 2024-03-06
Status change: Recruiting → Active, Not Recruiting 2022-12-07
Status change: Not Yet Recruiting → Recruiting 2021-10-14
Trial Details
NCT Number NCT05015686
Lead Sponsor Sinovac (Dalian) Vaccine Technology Co., Ltd.
Conditions Varicella
Enrollment 2,400 participants
Start Date 2021-09-30
Primary Completion 2022-02-09 (estimated)
Study Completion 2026-09-20 (estimated)
Updated on ClinicalTrials.gov 2024-03-08